ProtAffin AG strengthens Supervisory Board
ProtAffin AG announced that it has strengthened its Supervisory Board with the appointment of two new members. Dr Frank Walsh, CEO of Ossianix Inc. is joining the Supervisory Board as the new Chairman, and takes over the role from Kreske Nickelsen from Aescap Venture Management. At the same time, Tim Edwards, President and CEO of Cellzome Inc., will also be joining the ProtAffin Supervisory Board.
Prior to founding Ossianix, Frank Walsh was Executive Vice President and Head of Discovery Research Worldwide at Wyeth where he led a team of more than 1,500 scientists. Prior to joining Wyeth, Frank was at GlaxoSmithKline where he was Senior Vice President and Head of the Neurology Centre of Excellence for Drug Discovery (CEDD). He was also formerly Vice President and Head of Neuroscience Research at SmithKline Beecham. Frank has also had a distinguished academic career, and was the Research Dean at the United Medical and Dental Schools of Guys and St. Thomas' Hospitals in London and was the Sir William Dunn Professor of Experimental Pathology. Frank is also the Executive Chairman of Covagen AG in Zürich.
In addition to being CEO of Cellzome, Tim Edwards is the Chairman of the BioIndustry Association (BIA), the trade association for innovative enterprises in the UK's Bioscience sector. Tim has held various Board positions at British Biotech, and before that was an Investment Banker in London specialising in the healthcare sector. This followed 14 years as an entrepreneur in other industrial sectors, managing and developing three privately-held businesses in which he was a major shareholder.
Other news from the department people
